FDA Brief

Warning letters Biologics

FDA warning letter to

Stephen J. Fallon, Ph.D.

High riskIssued Aug 27Posted Sep 8Center for Biologics Evaluation and Research (CBER)

FDA warns clinical investigator Stephen J. Fallon, Ph.D. over consent and record failures in an HIV self-test study.

What happened

FDA inspected Fallon's clinical study site for Protocol CLS-003 (an INSTI HIV Self-Test usability study) from June 2 to June 13, 2025, and issued a Form FDA 483 listing observations at the close. FDA found that 35 of 42 consent forms were dated by study staff instead of the subjects, that some subjects were never given a copy of their signed consent, and that staff filled in the subjects' own HIV self-test result forms. FDA also said Fallon never responded to the 483 observations, and he told investigators he did not think a formal response was necessary.

What FDA found

  1. Consent forms were not signed and dated by the subjects themselves; study staff wrote in the consent dates for 35 of 42 subjects, and one form had no consent date at all.

    21 CFR 50.27(a); 21 CFR 812.100
  2. Subjects were not given a copy of their signed consent form; staff told some subjects to sign a new form to keep for their records.

    21 CFR 50.27(a)
  3. The consent form was changed after IRB approval (who gets paid, what type of payment, and when) and the changed form was used without IRB approval.

    21 CFR 812.110(b); 21 CFR 50.27
  4. Study staff filled in the participant HIV self-test result forms that the protocol required subjects to complete themselves, and Fallon did not catch this during the study.

    21 CFR 812.100; 21 CFR 812.110(b)
  5. Device shipping and accountability records were missing lot numbers, so FDA could not confirm which device lots each subject used or that the devices arrived in good condition.

    21 CFR 812.140(a)(2) and (a)(3)
  6. Staff initials on study records did not match the delegation log, and white-out was used to change entries, so FDA could not tell who made entries or what was originally recorded.

    21 CFR 812.140(a)(2) and (a)(3)

What FDA wants

Within 15 business days of receiving the letter, Fallon must write to CBER describing the corrective and preventive actions taken or planned, with supporting documentation, and send copies to two FDA email addresses. If he cannot finish in that time, he must explain the delay and give a completion date.

Who should pay attention

  • sponsors of diagnostic and device usability studies run at clinical sites
  • IRBs that review and approve consent forms
  • other clinical investigators and study coordinators running self-test studies

This is a summary. Read the original letter on fda.gov.

Similar letters to other companies

  1. Pratik Doshi, M.D. / Alembic Pharmaceuticals Ltd.

    FDA warned investigator Dr. Pratik Doshi at Alembic's Vadodara site that a bioequivalence study consent form wrongly said nothing was experimental.

    High risk
  2. Adnan Dahdul, MD

    FDA warns clinical investigator Dr. Adnan Dahdul over consent, eligibility and record failures in a biologics study.

    High risk
  3. Sourav K. Mishra, M.D. / All India Institute of Medical Sciences

    FDA warned clinical investigator Dr. Sourav K. Mishra at AIIMS Bhubaneswar over a doxorubicin liposome bioequivalence study that broke protocol and consent rules.

    High risk
  4. Mukesh B. Chandre, M.D., MBBS/Ashirwad Hospital & Research Centre

    FDA warned clinical investigator Dr. Mukesh Chandre over informed consent failures in a doxorubicin liposome bioequivalence study.

    High risk